Researchers from the Johns Hopkins Kimmel Cancer Center and the Johns Hopkins University School of Medicine have developed a computational model to help predict which patients with liver cancer may benefit most from combination immunotherapy and targeted treatment. The platform simulates tumor behavior and treatment responses, offering a potential new tool to guide more personalized cancer care.
